CELEXT07 a new botanical agent with functional
role in plant physiology; Mondias to target both the biostimulation
and antimicrobial agricultural market; CELEXT07 an eco-friendly
agent for the cannabis industry.
MONTREAL, Feb. 12, 2019 /CNW/ - Mondias Naturals
Inc ("Mondias" or "NHP"), (TSXV: NHP),
announces that the research collaboration with McGill University has led to the identification of
CELEXT07 signatory metabolite compounds, antibiotic properties and
functional roles in plant physiology. This will lead to the
development of several commercial products to meet emerging needs
in bio-agricultural and organic markets and offer new chemical free
solutions for the cultivation and food storage industries.
The chemical classes of compounds identified in the CELEXT07
extract confirms the botanical agent's properties associated with
plant defense against biotic stress by boosting the plant's
resistance as well as a biostimulant effect on growth. The
identification of these compounds supports the previous research
demonstrating CELEXT07's biostimulant and antifungal protective and
treatment properties.
Mr. Jean-Philippe Gravel, CEO of
Mondias Naturals stated, "These results validate Mondias' strategy
to develop natural products for agricultural markets including
post-harvest sub-markets. The CELEXT07 botanical extract will make
a significant contribution to the bio-agricultural and organic
markets and allow growers to offer horticultural products grown
with no chemical agents. We are excited by this advancement
since CELEXT07 is an eco-friendly alternative to synthetic
fungicides."
Postharvest diseases caused by storage fungi are responsible for
the estimated loss of about 20 to 25% of harvested fruits and
vegetables, and will certainly affect Canada's new cannabis industry. Some
fungi may produce mycotoxins that can cause toxicity to both
animals and humans. Mycotoxin contaminations can occur in the
field and greenhouse, before and after harvest, and also during
post-harvest activities and storage. Mondias has been
developing its CELEXT07 products to help prevent fungal growth on
plants through its proven ability to increase plants' defense
system.
As previously reported in its December 5,
2018 news release, CELEXT07, when used as a soil drench
agent, significantly reduced lesions caused by fungi on two
greenhouse growing plants, tomato and lettuce, and significantly
reduced lesions on detached leaves. Mondias has been
expanding its research activities to target food and crop
storage. Mr. Jean-Philippe
Gravel, CEO of Mondias Naturals stated, "These results
suggest that CELEXT07 botanical extract may become a low-risk
solution to the new Canadian and USA cannabis agricultural
industries."
The market potential for CELEXT07 is considerable considering
that these infections result in annual economic losses between
$10 billion to $100 billion worldwide (L. Hua et al. 2018) and
that about one-third of the food produced worldwide for human
consumption is lost after harvest (Gastavsson et al., 2011).
About Mondias Natural Products Inc. Mondias
specializes in the commercialization and development of evidence
based botanical products for the health care, bio agriculture and
organic markets. The company is already selling both oral and
topical botanical agents to help manage unmet medical needs through
Holizen Laboratories, one of its divisions. Mondias is also
developing botanical based specialty fertilizers for use on
household plants, urban gardens, lawns, golf courses, nurseries or
greenhouses in collaboration with McGill's Faculty of Agricultural and Environmental
Sciences.
For more information, visit: mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking
information. All statements, other than of historical fact, that
address activities, events or developments that the Company
believes, expects or anticipates will or may occur in the future
(including, without limitation, statements regarding potential
acquisitions and financings) are forward-looking statements.
Forward-looking statements are generally identifiable by use of the
words "may", "will", "should", "continue", "expect", "anticipate",
"estimate", "believe", "intend", "plan" or "project" or the
negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company's ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in
the forward-looking statements. Factors that could cause actual
results or events to differ materially from current expectations
include, among other things, without limitation, the inability of
the Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, the success of this joint
venture, the ability to obtain orphan drug status, the
applicability of the discoveries made therein, the successful and
timely completion and uncertainties related to the regulatory
process, the timing of clinical trials, the timing and outcomes of
regulatory or intellectual property decisions and other risks
disclosed in the Company's public disclosure record on file with
the relevant securities regulatory authorities. Although the
Company has attempted to identify important factors that could
cause actual results or events to differ materially from those
described in forward-looking statements, there may be other factors
that cause results or events not to be as anticipated, estimated or
intended. Readers should not place undue reliance on
forward-looking statements. While no definitive documentation has
yet been signed by the parties and there is no certainty that such
documentation will be signed. The forward-looking statements
included in this news release are made as of the date of this news
release and the Company does not undertake an obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities legislation.
SOURCE Mondias Natural Products Inc.